Cargando…

Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [(11)C]PHNO PET

The use of positron emission tomography (PET) in early-phase development of novel drugs targeting the central nervous system, is well established for the evaluation of brain penetration and target engagement. However, when novel targets are involved a suitable PET ligand is not always available. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rabiner, Eugenii A., Uz, Tolga, Mansur, Ayla, Brown, Terry, Chen, Grace, Wu, Jingtao, Atienza, Joy, Schwarz, Adam J., Yin, Wei, Lewis, Yvonne, Searle, Graham E., Dennison, Jeremy M. T. J., Passchier, Jan, Gunn, Roger N., Tauscher, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117280/ https://www.ncbi.nlm.nih.gov/pubmed/34675381 http://dx.doi.org/10.1038/s41386-021-01204-1

Ejemplares similares

S180. THE SELECTIVE GPR139 AGONIST TAK-041 REVERSES ANHEDONIA AND SOCIAL INTERACTION DEFICITS IN RODENT MODELS RELATED TO NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
por: Schiffer, Hans, et al.
Publicado: (2020)

S39. GPR139 AN OPHAN GPCR AFFECTING NEGATIVE DOMAINS OF SCHIZOPHRENIA
por: Atienza, Joy, et al.
Publicado: (2018)

Pan-Cancer Analysis and Drug Formulation for GPR139 and GPR142
por: Kaushik, Aman Chandra, et al.
Publicado: (2021)

A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK‐041 in healthy participants and patients with stable schizophrenia
por: Yin, Wei, et al.
Publicado: (2022)

Habenula GPR139 is associated with fear learning in the zebrafish
por: Roy, Nisa, et al.
Publicado: (2021)

An evaluation of the brain distribution of [(11)C]GSK1034702, a muscarinic-1 (M(1)) positive allosteric modulator in the living human brain using positron emission tomography
por: Ridler, Khanum, et al.
Publicado: (2014)

DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats
por: Sharma, Puneet K., et al.
Publicado: (2020)

Pharmacology and function of the orphan GPR139 G protein‐coupled receptor
por: Vedel, Line, et al.
Publicado: (2019)

Adenosine A(2A) receptor in schizophrenia: an in vivo brain PET imaging study
por: Marques, Tiago Reis, et al.
Publicado: (2021)

Toward the Optimization of (+)-[(11)C]PHNO Synthesis: Time Reduction and Process Validation
por: Pfaff, Sarah, et al.
Publicado: (2019)

Mutagenesis of GPR139 reveals ways to create gain or loss of function receptors
por: Wang, Lien, et al.
Publicado: (2019)

Catabolism and Detoxification of 1-Aminoalkylphosphonic Acids: N-Acetylation by the phnO Gene Product
por: Hove-Jensen, Bjarne, et al.
Publicado: (2012)

Influence of Nicotine Metabolism Ratio on [(11)C]-(+)-PHNO PET Binding in Tobacco Smokers
por: Di Ciano, Patricia, et al.
Publicado: (2018)

Re-evaluation of Adrenocorticotropic Hormone and Melanocyte Stimulating Hormone Activation of GPR139 in Vitro
por: Nepomuceno, Diane, et al.
Publicado: (2018)

Identification of a novel scaffold for a small molecule GPR139 receptor agonist
por: Nøhr, Anne Cathrine, et al.
Publicado: (2019)

Quantification of human brain PDE4 occupancy by GSK356278: A [(11)C](R)-rolipram PET study
por: van der Aart, Jasper, et al.
Publicado: (2017)

Molecular insights into ligand recognition and G protein coupling of the neuromodulatory orphan receptor GPR139
por: Zhou, Yali, et al.
Publicado: (2021)

First evaluation of PET-based human biodistribution and radiation dosimetry of (11)C-BU99008, a tracer for imaging the imidazoline(2) binding site
por: Venkataraman, Ashwin V., et al.
Publicado: (2018)

A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects
por: Yurgelun-Todd, Deborah A., et al.
Publicado: (2019)

B Physics in ATLAS (ATL-PHYS-94-041)
por: Eerola, Paule Anna Mari, et al.
Publicado: (1994)

AB041. Evolution of PDE5 inhibitors in Korea
por: Moon, Du Geon
Publicado: (2015)

SUN-041 Estrogen Pharmacogenetics in Patients with Turner Syndrome
por: Scalco, Renata, et al.
Publicado: (2019)

MON-LB041 Pheochromocytoma - Illusive Myriad of Symptoms
por: Gunda, Mouna, et al.
Publicado: (2020)

Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo
por: Guo, Qi, et al.
Publicado: (2012)

Evaluation of dopamine D(3) receptor occupancy by blonanserin using [(11)C]-(+)-PHNO in schizophrenia patients
por: Sakayori, Takeshi, et al.
Publicado: (2020)

Acute acetate administration increases endogenous opioid levels in the human brain: A [(11)C]carfentanil molecular imaging study
por: Ashok, Abhishekh H, et al.
Publicado: (2021)

In vivo Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist
por: Shoblock, James R., et al.
Publicado: (2019)

O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS
por: Chika Onwordi, Ellis, et al.
Publicado: (2020)

The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study
por: Onwordi, Ellis Chika, et al.
Publicado: (2021)

P01-041 – Patient management and rare FMF symptoms
por: Moradian, MM, et al.
Publicado: (2013)

PW02-041 - Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

AB041. Perioperative nursing care of penile pacemaker implantation
por: Han, Di
Publicado: (2017)

P041 The Impact of Simulated Night Shifts on Executive Functioning
por: Greer, E, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
por: Fedyk, Eric R., et al.
Publicado: (2020)

Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking study
por: Marques, Tiago Reis, et al.
Publicado: (2021)

Protection of Primary Dopaminergic Midbrain Neurons by GPR139 Agonists Supports Different Mechanisms of MPP(+) and Rotenone Toxicity
por: Bayer Andersen, Kirsten, et al.
Publicado: (2016)

Novel Agonist Bioisosteres and Common Structure-Activity Relationships for The Orphan G Protein-Coupled Receptor GPR139
por: Shehata, Mohamed A., et al.
Publicado: (2016)

GPR139 and Dopamine D2 Receptor Co-express in the Same Cells of the Brain and May Functionally Interact
por: Wang, Lien, et al.
Publicado: (2019)

The influence of conditioned stimuli on [(11)C]-(+)-PHNO PET binding in tobacco smokers after a one week abstinence
por: Di Ciano, Patricia, et al.
Publicado: (2021)

A041 DETECTION OF SARS-COV-2 ANTIBODIES IN IMMUNOGLOBULIN PRODUCTS
por: Cousins, K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pquvbhkeao6c0275a89eu2fr3c